Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2012. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific equity transaction and does not contain consolidated financial statements.
Material Changes
The filing details a change in the shareholding of Mrs. V. Whyte, a PDMR. On March 9, 2012, she received an award of 11,800 Ordinary Shares under the GlaxoSmithKline 2009 Performance Share Plan. The award was based on a share price of £14.12 per share, reflecting the closing middle market price on March 8, 2012.
Guidance, Outlook, and Risks
The filing does not provide guidance, outlook, or management commentary on business performance. The primary contingency noted is that the vesting of the awarded shares is subject to meeting performance criteria over a three-year period.
Investor Verification Points
- Verify the vesting conditions and performance criteria for the 2009 Performance Share Plan.
- Confirm the total number of shares awarded to Mrs. V. Whyte (11,800) and the valuation date (March 8, 2012).
- Note that this filing does not contain financial results; refer to the company's Form 20-F or quarterly reports for financial data.